Â鶹ÒùÔº

Innovations that become industry standards

Our mission at Cirena is to provide tomorrow's nucleic acids technology to customers, today. We provide high-purity chemically synthesized RNA out to 300 nucleotides in length, from microgram to gram quantities. Along with these benefits, we can provide site specific modifications for your RNA. Ìý

We are here to support the robust development of the next generation of RNA based therapeutics and technologies. Our laboratories sit within the heart of the "RNA world" at the University of Colorado Biofrontiers Institute. We see our role as enablers in the field of nucleic acid technologies, to innovate and make what once seemed impossible, possible.Ìý

°ä´Ç²Ô³Ù²¹³¦³Ù:Ìý800-400-8319
mdellinger@cirena.com

See Like No Other

Double Helix is a team of top talent from a range of fields coming together to advance discovery and research in precision 3D nano-imaging. We have recognized world experts in super-resolution, first-rate engineers in optics, 3D imaging, software,and advisors from the research and business world. We are experts in our fields, collaborators in others, and excited by discovery.

We create accessible diagnostics for the early detection of disease.

Our team is composed of experts in the fields of infectious disease, immunology, molecular biology, and healthcare product design. We have extensive experience analyzing human saliva to detect signatures of infectious disease, with a focus on pre-symptomatic detection of infection.

Darwin Biosciences was founded in March of 2020. We leveraged our expertise in handling and processing human saliva to quickly develop and deploy a turnkey solution to SARS-CoV-2 testing () that propelled us through an initial growth phase. We have now turned our focus to developing a next-generation diagnostic platform to prepare the world for the next pandemic. We’re equipped with technology licensed from the University of Colorado Boulder.

Modendo develops ultrathin endomicroscopes that provide high-resolution optical imaging and photo-stimulation in currently inaccessible regions of the body. Modendo’s disruptive technology,Ìýdeveloped by experts in the optics and neuroscience community, offers a new class of fundamentally less invasive optical imaging probes.

The leap to environmentally sound materials.

Silvis is creating bio-based emulsions to replace petroleum materials in coatings, adhesives, binders, and paints. Just about every piece of plastic begins as a fossil fuel, with greenhouse gases emitted at every step of the way.Ìý Silvis is working on a lower cost, sustainable and bio-degradable emulsion platform which can be used in multiple applications for a variety of markets.Ìý

Petroleum is a component of plastics that exist in all these products, and GHGs are not the only pollutant. The extensive use of plastics in almost everything we touch ends up in our landfills and oceans. Silvis believes they can help cleanup parts of the whole pollution chain, reducing landfill pollution and chemical waste in our waterways.

We develop next-generation therapeutics, inspired by psychedelics from nature.

Our mission is to extend the healing potential of psychedelics to a broader patient population.

Our objective is to develop widely-accessible medications that offer an improved treatment alternative to current SSRIs, using psychedelic molecules as the starting point.

The lncRNA Company.

Harnessing the power of lncRNA to flip the switch on disease-causing genes.

Ìý

Next generation mining for critical minerals.

The pulse of life beats stronger. When you believe anything is possible.

Reimagining what’s possible in cardiovascular medicine: We are a heart health company working to make cardiovascular disease preventable, curable and no longer the leading cause of death in the world.

Kardigan is on a mission to develop multiple targeted treatments in parallel that bring people with cardiovascular diseases closer to the cures they deserve. We have a cutting-edge discovery and translational research platform, a pipeline of late-stage candidates, and an industry-leading team that is driven to improve the lives of patients. We are relentless in our pursuit to develop a portfolio of medicines that modify the underlying cardiovascular disease, moving the field beyond symptom management toward functional cures.

Ìý